This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana's (HUM) Q3 Earnings Surpass Estimates, Decline Y/Y
by Zacks Equity Research
Humana's (HUM) third-quarter earnings reflect improved revenues, partly offset by expenses.
Select Medical's (SEM) Q3 Earnings Beat Mark, Improve Y/Y
by Zacks Equity Research
Select Medical's (SEM) third-quarter 2020 earnings gain traction from better revenues at its Critical Illness Recovery and Rehabilitation Hospital segments.
Teladoc (TDOC) Q3 Earnings Beat Estimates, Hikes '20 Guidance
by Zacks Equity Research
Teladoc's (TDOC) third-quarter results reflect robust revenues and solid uptick in patient visits, partially offset by elevated costs.
Acadia Healthcare's (ACHC) Shares Up on Q3 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) shares gain on third-quarter earnings beat, which has been driven by higher revenues. However, elevated costs have partially offset the results.
Universal Health's (UHS) Q3 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Universal Health's (UHS) third-quarter results reflect higher revenues and lower expenses.
Universal Health Services (UHS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 41.18% and 6.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More
by Zacks Equity Research
Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.
Universal Health (UHS) to Report Q3 Results: What to Expect
by Zacks Equity Research
Universal Health's (UHS) third-quarter earnings results are likely to reflect depressed revenues and weak admissions.
Here's Why You Should Retain Universal Health (UHS) for Now
by Zacks Equity Research
Riding high on its solvency position, strong segments and strategic initiatives, Universal Health (UHS) holds potential to reap benefits.
Universal Health Services (UHS) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Universal Health Services (UHS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: HCA, UHS, ACHC and THC
by Zacks Equity Research
Zacks Industry Outlook Highlights: HCA, UHS, ACHC and THC
Encompass Health Offers Senior Unsecured Notes Worth $400M
by Zacks Equity Research
Encompass Health (EHC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.
Acadia Healthcare Offers Senior Unsecured Notes for $475M
by Zacks Equity Research
Acadia Healthcare (ACHC) exhibits sharp business acumen by issuing senior notes to procure funds.
4 Hospital Stocks to Gain from Improving Admissions, Federal Aid
by Sapna Bagaria
Federal relief, higher admissions and cost containment are likely to aid the Zacks Medical-Hospital industry. HCA, UHS, CYH and THC are well-positioned to gain from a revival in admissions.
Zacks Industry Outlook Highlights: CYH, HCA, UHS and THC
by Zacks Equity Research
Zacks Industry Outlook Highlights: CYH, HCA, UHS and THC
Centene (CNC) Offers Senior Unsecured Notes Valued $2.2B
by Zacks Equity Research
Centene (CNC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.
UHS or THC: Which is a Better-Positioned Stock Right Now?
by Zacks Equity Research
Universal Health (UHS) and Tenet Healthcare (THC) are poised to grow. On comparative evaluation, we try to discover which is a more profitable bet based on the fundamentals.
Why Should You Retain MEDNAX (MD) in Your Portfolio Now?
by Zacks Equity Research
Riding on restructuring as well as cost-cutting initiatives, MEDNAX (MD) holds potential to reap benefits for investors.
Why Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Riding high on segmental contributions and a solid balance sheet, Universal Health (UHS) has potential to reap benefits for investors.
MEDNAX Divests Radiology Business to Focus on Core Operations
by Zacks Equity Research
MEDNAX (MD) reaches an agreement with Radiology Partners to sell its MEDNAX Radiology Solutions, which will lower its debt load and restructure its business.
MEDNAX (MD) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
MEDNAX (MD) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: HUM, SEM, UHS and FSNUY
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HUM, SEM, UHS and FSNUY
Why Should You Hold on to Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Riding high on divestitures and cost-reduction, Tenet Healthcare (THC) holds enough potential to reap benefits for yield-seeking investors.
How to Invest After the Market Selloff
by Sejuti Banerjea
Tried and tested methods always work best when you're faced with increased uncertainty and volatility.
Impressive Sales Growth Makes These 5 Stocks Worth Buying
by Swayta Shah
Sales growth is an important indicator of a company's health and ability to sustain the business.